Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL tri...
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
About this item
Full title
Author / Creator
Mailankody, Sham , Matous, Jeffrey V. , Chhabra, Saurabh , Liedtke, Michaela , Sidana, Surbhi , Oluwole, Olalekan O. , Malik, Shahbaz , Nath, Rajneesh , Anwer, Faiz , Cruz, Jose Carlos , Htut, Myo , Karski, Erin E. , Lovelace, Wade , Dillon, Myles , Butz, Eric , Ying, Wendy , Balakumaran, Arun and Kumar, Shaji K.
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating doses of ALLO-715 after lymphodepletion with an anti-CD52 antibody (ALLO-647)-containing regimen in 43 patients with relapsed/refractory multiple myeloma as part A of the ongoi...
Alternative Titles
Full title
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2778137820
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2778137820
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-022-02182-7
